Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Drug testing services can save lives but NSW and Victoria stubbornly refuse to get on board

NSW Health Minister Ryan Park tells Crikey he isn’t personally convinced of the need for drug testing — even as experts line up to back the services.

Crikey

Johnson & Johnson not to enforce patents on TB drug

“The announcement will finally pave the way for unfettered access to affordable generic versions of bedaquiline for all people”

The Hindu

These 5 Stocks Are Setting Up This Buying Opportunity After Strong Runs

After a run, stocks can offer a new buying opportunity with a pullback to the 50-day line. Novo Nordisk and 4 S&P 500 stocks have done that.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Have a complaint about CVS? So do pharmacists: Many just walked out

After a large walkout forced at least a dozen stores to shut down in the Kansas City area, CVS promises change. But critics say the crisis in staffing and unfair pay extends beyond that market.

WEKU

Vivek Ramaswamy is furiously defending his business ties in China. What are they?

‘Vivek’s first business had a subsidiary in China’ which was closed ‘as the risks of doing business in China became apparent,’ Ramaswamy spokesperson says

The Independent UK

3 Biotech Stocks to Buy Instead of Palatin Technologies (PTN)

While Palatin Technologies (PTN) has faced challenges with declining share price, negative analyst projections, and limited profitability, it's worth noting the consistent growth in the broader biotech industry. Thus, investors could find more stable returns in robust biotech stocks Protalix BioTherapeutics (PLX), Exelixis (EXEL), and Jazz Pharmaceuticals (JAZZ) instead. Read…

StockNews.com

3 A-Rated Pharma Buys for October

The growing adoption of innovative drugs and the heightened demand for personalized medicines are expected to boost the pharma industry. Therefore, it might be wise to buy fundamentally strong pharma stocks Neurocrine Biosciences (NBIX), Novo Nordisk (NVO), and AstraZeneca PLC (AZN), which are rated an A (Strong Buy) in our…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

‘My posts are backed up with solid evidence, research’: Liver Doc on Himalaya Wellness suit

“Based on strong scientific evidence, or because of lack of it, I have been critical of several of Himalaya Wellness’ products,” said doctor-influencer Cyriac Abby Philips aka The Liver Doc, whose X account was suspended today for posting “defamatory remarks” against the ayurvedic pharma company.

Newslaundry

People with HIV offered hope of self-injected drug at home

GSK-controlled company works on developing patient-administered treatment by end of the decade

The Guardian - UK

Crispr Therapeutics, And CRISPR Gene-Editing, Face Their Make-Or-Break Moment

Crispr is facing its make-or-break moment and, experts say, a pivotal decision in December could spark more than just beleaguered CRSP stock.

Investors Business Daily

Common children’s antibiotic amoxicillin still in short supply for the second year

While pharmacies say they can still fill most prescriptions for amoxicillin, the most-prescribed drug in the country, the shortage could worsen when the viral season hits this winter, experts say.

Chicago Sun-Times

Biohaven, Yet Another Rival To Argenx In Autoimmune Drugs, Just Rocketed 33%

Biohaven could rival Argenx and Immunovant after unveiling results Wednesday for an autoimmune diseases drug. BHVN stock rocketed.

Investors Business Daily

Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering

Immunovant stock reversed lower Wednesday after the company announced a $300 million offering. IMVT stock almost doubled Tuesday.

Investors Business Daily

New York drug consumption rooms to influence Glasgow pilot, First Minister says

GLASGOW’S pioneering drug consumption room will be shaped by research carried out in New York City, the First Minister has said.

The National (Scotland)

Get all your
news in one place.

100’s of premium titles.
One news app.

Newcastle Herald

'Easier access': Oral contraceptives from pharmacies

'Recognition of the capabilities that pharmacies have.'

Investors Business Daily

The $660 Million Opportunity That's Driving IBD Stock Of The Day Neurocrine Biosciences Higher

Neurocrine is Tuesday's IBD Stock Of The Day. After it unveiled promising results for a genetic disease drug, NBIX stock is on the rise.

Salon

The first OTC birth control is coming

An OTC birth control pill will help ensure more people can access the contraception they need without barriers

WEKU

An overdose drug is finally over-the-counter. Is that enough to stop the death toll?

Narcan is now available in drug stores without a prescription. The nasal spray can save a life by stopping an opioid overdose. But will people pay the price and ask for it by name?

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

The Surprise That Prompted Morphic Therapeutic To Dump 55% Over Two Days

Morphic stock plummeted Monday after the company's ulcerative colitis drug underperformed a rival. MORF stock has lost 55% over two days.

AAP

Prescription pilot just the tonic for pharmacists

Pharmacists will be able to prescribe medications and administer more vaccines under a pilot program being expanded throughout Queensland.

The Hindu

Draft patent amendment rules undermine pre-grant opposition

Draft patent rules threaten pre-grant opposition, a key public health safeguard. Big pharma seeks to remove essential safeguards from India’s patent laws, creating needless hurdles in pre-grant opposition. Draft rules introduce variable fees, power to determine maintainability of representation by individuals/groups. This threatens access to quality-assured, affordable generics & extends…

StockNews.com

Bionano Genomics (BNGO) Challengers: 3 Biotech Innovators to Buy Instead

With the rising aging population and the emergence of new diseases, the biotech industry appears poised for steady growth. Therefore, three quality biotech stocks, Vanda Pharmaceuticals (VNDA), Organogenesis Holdings (ORGO), and Exelixis (EXEL), could be better catches than Bionano Genomics (BNGO). Read on….

The Independent UK

Walgreens and CVS warned about selling illegal eye products

Warning letters sent to the companies claimed certain products they sell are ‘especially concerning from a public health perspective’

The Independent UK

Revolving door redux: The DEA's recently departed No. 2 returns to a Big Pharma consulting firm

Washington’s revolving door kept spinning this week as the Drug Enforcement Administration’s recently departed second-in-command returned for another stint with a high-powered consulting firm where he previously advised OxyContin maker Purdue Pharma

Newsroom.co.nz

Workplace drug testing quagmire deepens

Medical cannabis is behind an uptick in workplace drug detection and the solution isn't clear-cut, reports Andrew Bevin

1 … 26 27 28 29

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Scottish Government

the Chinese Communist Party

137 stories

Purdue Pharma

121 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.